-
公开(公告)号:US11566003B2
公开(公告)日:2023-01-31
申请号:US16921297
申请日:2020-07-06
Applicant: Genentech, Inc.
Inventor: Bryan Chan , Joy Drobnick , Lewis Gazzard , Timothy Heffron , Jun Liang , Sushant Malhotra , Rohan Mendonca , Naomi Rajapaksa , Craig Stivala , John Tellis , Weiru Wang , BinQing Wei , Aihe Zhou , Matthew W. Cartwright , Michael Lainchbury , Emanuela Gancia , Eileen Seward , Andrew Madin , David Favor , Kin Chiu Fong , Yonghan Hu , Andrew Good
IPC: C07D217/22 , A61K31/549 , A61P35/00 , A61K45/06 , C07D401/04 , A61K31/4725 , A61K31/506 , A61K31/501 , C07D471/04 , C07D413/04 , C07D413/14 , A61K31/5377 , C07D417/04 , A61K31/4985 , C07D401/14 , C07D487/04 , A61K31/551 , C07D498/04 , A61K31/5383 , C07D405/14 , C07D519/00 , C07D498/14 , C07D513/04 , A61K31/554 , A61K31/55 , A61K31/472 , C07D409/14 , C07D491/04 , C07D487/14
Abstract: Isoquinoline compounds and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the isoquinoline compounds.
-
公开(公告)号:US11560391B2
公开(公告)日:2023-01-24
申请号:US17150380
申请日:2021-01-15
Applicant: Genentech, Inc.
Inventor: Jeffrey A. Stafford , James M. Veal , Lynnie Lin Trzoss , Christopher McBride , Richard M. Pastor , Steven Thomas Staben , Craig Stivala , Matthew Volgraf
IPC: C07D498/04
Abstract: The present disclosure relates to novel sulfonylurea compounds and related compounds useful in treating a disorder responsive to modulation of cytokines such as IL-1β and IL-18, modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process.
-
公开(公告)号:US20230002391A1
公开(公告)日:2023-01-05
申请号:US17340082
申请日:2021-06-06
Applicant: Genentech, Inc.
Inventor: Snahel Patel , Gregory Hamilton , Craig Stivala , Huifen Chen , Blake Daniels
IPC: C07D487/04 , C07D231/54 , C07D249/16 , A61P25/00
Abstract: The invention provides novel compounds having the general formula I: wherein R1, RB1, RB2, n, p, q, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds, and methods of using the compounds.
-
公开(公告)号:US20210277024A1
公开(公告)日:2021-09-09
申请号:US17156384
申请日:2021-01-22
Applicant: Genentech, Inc.
Inventor: Terry Kellar , Jun Liang , Sushant Malhotra , Rohan V. Mendonca , Michael Siu , Craig Stivala , John C. Tellis , BinQing Wei , Bryan K. Chan , Lewis J. Gazzard , Timothy Heffron , Graham Jones , Michael Lainchbury , Andrew Madin , Eileen Mary Seward , Matthew W. Cartwright , Emanuela Gancia , David Favor , Kin Chiu Fong , Andrew Good , Yonghan Hu
IPC: C07D519/00 , C07D471/04 , A61P37/04
Abstract: Naphthyridine compounds of formula (I). variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.
-
公开(公告)号:US20210253580A1
公开(公告)日:2021-08-19
申请号:US17156387
申请日:2021-01-22
Applicant: Genentech, Inc.
Inventor: Jun Liang , Sushant Malhotra , Rohan V. Mendonca , Naomi Rajapaksa , Michael Siu , Craig Stivala , John C. Tellis , BinQing Wei , Bryan K. Chan , Joy Alison Drobnick , Lewis J. Gazzard , Timothy Heffron , Graham Jones , Michael Lainchbury , Andrew Madin , Eileen Mary Seward , Matthew W. Cartwright , Emanuela Gancia , David Favor , Kin Chiu Fong , Andrew Good , Yonghan Hu
IPC: C07D487/04 , C07D513/04 , C07D519/00 , C07D487/14 , C07D498/14 , C07D401/12 , C07D401/14 , C07D405/14 , C07D498/04 , A61P37/04
Abstract: Isoquinoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the isoquinoline compounds.
-
公开(公告)号:US11072617B2
公开(公告)日:2021-07-27
申请号:US16175206
申请日:2018-10-30
Applicant: Genentech, Inc.
Inventor: Snahel Patel , Gregory Hamilton , Craig Stivala , Huifen Chen , Blake Daniels
IPC: C07D487/04 , C07D231/54 , C07D249/16 , A61P25/00
Abstract: The invention provides novel compounds having the general formula I: wherein R1, RB1, RB2, n, p, q, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds, and methods of using the compounds.
-
公开(公告)号:US10407424B2
公开(公告)日:2019-09-10
申请号:US15942321
申请日:2018-03-30
Applicant: Genentech, Inc.
Inventor: Bryan Chan , Naomi Rajapaksa , Michael Siu , Craig Stivala , John Tellis , Weiru Wang , BinQing Wei , Aihe Zhou , Matthew W. Cartwright , Emanuela Gancia , Graham Jones , Blake Daniels , Michael Lainchbury , Andrew Madin , Eileen Seward , David Favor , Kin Chiu Fong , Andrew Good , Yonghan Hu , Baihua Hu , Aijun Lu , Joy Drobnick , Lewis Gazzard , Timothy Heffron , Malcolm Huestis , Jun Liang , Sushant Malhotra , Rohan Mendonca
IPC: C07D471/04 , A61K31/55 , A61P35/00 , A61K31/444 , A61K31/4375 , A61K31/506 , C07D519/00 , A61K31/4545 , A61K31/4725 , A61K31/5383 , A61K31/496 , A61K31/5377 , A61K31/5025 , A61K31/551 , A61K45/06
Abstract: Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.
-
公开(公告)号:US12281101B2
公开(公告)日:2025-04-22
申请号:US17198238
申请日:2021-03-10
Applicant: Genentech, Inc.
Inventor: Snahel Patel , Gregory Hamilton , Craig Stivala , Huifen Chen , Guiling Zhao
IPC: C07D403/12 , A61K31/55 , A61K31/553 , A61P1/00 , A61P1/04 , A61P1/16 , A61P1/18 , A61P9/00 , A61P9/10 , A61P11/00 , A61P13/12 , A61P17/06 , A61P25/00 , A61P27/02 , A61P29/00 , A61P31/00 , A61P31/04 , A61P35/00 , A61P43/00 , C07D413/12 , C07D413/14 , C07D471/04 , C07D487/04 , C07D491/04 , C07D491/044 , C07D491/048 , C07D491/052 , C07D491/10 , C07D495/04 , C07D495/14 , C07D498/04 , C07D498/16 , C07D519/00
Abstract: The invention provides novel compounds having the general formula I: wherein R1, X, Z1, L, n, the A ring, the B ring, and the C ring are as described herein, pharmaceutical compositions including the compounds and methods of using the compounds.
-
公开(公告)号:US20220370420A1
公开(公告)日:2022-11-24
申请号:US17204089
申请日:2021-03-17
Applicant: Genentech, Inc.
Inventor: Sushant Malhotra , Craig Stivala , BinQing Wei , Bryan K. Chan , Timothy Heffron , Michael Lainchbury , Andrew Madin , Terry Aaron Panchal , Eileen Mary Seward , Toby Blench , Matthew W. Cartwright , Elsa Amandine Dechaux , Richard Elliott , Emanuela Gancia
IPC: A61K31/437 , A61K45/06 , C07D471/10 , C07D491/20 , C07D519/00 , C07D487/20 , C07D471/20 , A61K31/5377 , A61K31/444 , A61K31/496 , A61K31/513 , A61K31/4985
Abstract: Spirocyclic 2,3-dihydro-7-azaindole compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the spirocyclic 2,3-dihydro-7-azaindole compounds.
-
公开(公告)号:US11098058B2
公开(公告)日:2021-08-24
申请号:US16034207
申请日:2018-07-12
Applicant: Genentech, Inc.
Inventor: Snahel Patel , Gregory Hamilton , Guiling Zhao , Huifen Chen , Blake Daniels , Craig Stivala
IPC: C07D498/04 , C07D487/04 , A61P25/16 , A61P25/28 , C07D235/12 , C07D471/04 , A61P17/06 , A61P21/00 , A61P19/02 , A61P1/00
Abstract: The invention provides novel compounds having the general formula I: wherein R1, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds, and methods of using the compounds.
-
-
-
-
-
-
-
-
-